On December 19, 2019 Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics, reported that its chief executive officer, David Arthur, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California (Press release, Flex Pharma, DEC 19, 2019, View Source [SID1234552503]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Mr. Arthur will highlight recent corporate achievements and anticipated milestones from its clinical development pipeline, which is led by Seclidemstat, a potent reversible inhibitor of the LSD1 enzyme. Seclidemstat is currently the subject of an ongoing Phase 1/2 clinical trial in Ewing sarcoma, a rare and deadly pediatric bone cancer for which there is no approved targeted treatment. Seclidemstat is also being studied in a second Phase 1 clinical trial in advanced solid tumors (AST), including prostate, breast and ovarian cancers. Salarius recently achieved important dose escalation and trial enrollment events for each program, positioning the company to report early patient safety and efficacy data from both clinical trials in 2020.

Details of the presentation are as follows:

Event: Biotech Showcase 2020
Date: Tuesday, January 14, 2020
Time: 11:30 a.m. (PST)
Track: Franciscan A
Location: Hilton San Francisco Union Square